Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

NCT01750086 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: Teriparatide 40-mcg subcutaneous injection
DRUG: Denosumab Injection
DRUG: Alendronate Oral Tablet

Sponsor

Massachusetts General Hospital